Profound Medical Corp. (PROF)

NASDAQ: PROF · IEX Real-Time Price · USD
4.65
-0.02 (-0.43%)
Nov 29, 2022 3:10 PM EDT - Market open
-0.43%
Market Cap 98.14M
Revenue (ttm) 4.87M
Net Income (ttm) -24.57M
Shares Out 20.85M
EPS (ttm) -1.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 53,650
Open 4.69
Previous Close 4.67
Day's Range 4.5 - 4.76
52-Week Range 3.1 - 12.27
Beta 1.81
Analysts Buy
Price Target 12.64 (+167.8%)
Earnings Date Nov 3, 2022

About PROF

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief assoc... [Read more]

Industry Health Care Equipment & Supplies
Employees 146
Stock Exchange NASDAQ
Ticker Symbol PROF
Full Company Profile

Financial Performance

In 2021, PROF's revenue was 6.87 million, a decrease of -5.90% compared to the previous year's 7.30 million. Losses were -30.52 million, 25.0% more than in 2020.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for PROF stock is "Buy." The 12-month stock price forecast is 12.64, which is an increase of 167.80% from the latest price.

Price Target
$12.64
(167.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Profound Medical to Present at the 2022 Jefferies London Healthcare Conference

TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

2 weeks ago - GlobeNewsWire

Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of 29.41% and 15.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

1 month ago - GlobeNewsWire

Four Year Follow-Up Data from Profound Medical's TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Tren...

TORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

2 months ago - GlobeNewsWire

Profound Medical to Participate in September Investor Conferences

TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

2 months ago - GlobeNewsWire

Profound Medical Provides TULSA-PRO® Reimbursement Update

TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

2 months ago - GlobeNewsWire

Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Earnings Preview: Profound Medical (PROF) Q2 Earnings Expected to Decline

Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Profound Medical to Release Second Quarter 2022 Financial Results on August 4 – Conference Call to Follow

TORONTO, July 14, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

4 months ago - GlobeNewsWire

Profound Medical to Participate in the Cowen 7th Annual FutureHealth Conference

TORONTO, June 16, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

5 months ago - GlobeNewsWire

Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference

TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

5 months ago - GlobeNewsWire

Profound Medical Annual and Special Meeting of Shareholders Voting Results

TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of S...

6 months ago - GlobeNewsWire

Profound Medical Clarifies Recent Insider Buying

TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its ins...

6 months ago - GlobeNewsWire

TULSA-PRO® Was Front and Center at AUA2022

Activities Highlighting Profound's Ground-Breaking Technology Included a Semi-Live TULSA Procedure Performed by UT Southwestern's Dr. Kenneth A. Goldberg During Meeting's Plenary Session Activities High...

6 months ago - GlobeNewsWire

Profound Medical (PROF) Reports Q1 Loss, Lags Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of 11.11% and 9.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Profound Medical Announces First Quarter 2022 Financial Results

TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, i...

6 months ago - GlobeNewsWire

New Strong Sell Stocks for April 27th

FRPT, PING, and PROF have been added to the Zacks Rank #5 (Strong Sell) List on April 27, 2022

Other symbols: FRPTPING
7 months ago - Zacks Investment Research

Profound Medical to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

7 months ago - GlobeNewsWire

Profound Medical to Release First Quarter 2022 Financial Results on May 9 – Conference Call to Follow

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

7 months ago - GlobeNewsWire

Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results

TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

8 months ago - GlobeNewsWire

Profound Medical to Participate in March Investor Conferences

TORONTO, March 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

8 months ago - GlobeNewsWire

Profound Medical (PROF) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Profound Medical to Release Fourth Quarter and Full Year 2021 Financial Results on March 3 – Conference Call to Follow

TORONTO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

9 months ago - GlobeNewsWire

Profound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

9 months ago - GlobeNewsWire

Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Proce...

TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

10 months ago - GlobeNewsWire